Lab testing becomes a genuine profit center only after you know which CLIA certificate your practice operates under, because that decision, not a markup percentage, sets the ceiling on what you can legally run in-house versus send out. Most profitability guides for functional medicine skip this step and jump straight to markup tactics that will not survive a compliance review in every state. Start with the regulatory ceiling, then build the revenue strategy inside it.
The regulatory ceiling before the revenue strategy
Direct answer: any lab testing performed on human specimens for the diagnosis, prevention, or treatment of disease requires CLIA certification, and the certificate type your practice holds determines exactly which tests you can legally run on-site.
The Clinical Laboratory Improvement Amendments program, administered by CMS, covers roughly 320,000 laboratory entities nationwide and applies to any facility testing human specimens for those purposes, which includes a functional medicine practice running even a single point-of-care test (CMS, CLIA overview). A practice cannot decide to add an in-house test menu and figure out the certification question afterward. The certificate type comes first, and it constrains everything that follows.
Certificate of Waiver vs. moderate complexity: what you can run on-site
Direct answer: only tests the FDA and CDC classify as CLIA-waived can be run under a basic Certificate of Waiver, and that classification, not clinical usefulness, is what determines whether a test can stay in your office or must be sent out.
The CDC maintains the definition and current list logic for waived tests, which are simple enough in design that the risk of an incorrect result is low even when performed by staff without specialized laboratory training (CDC, Waived Tests). Anything more complex, most advanced functional medicine panels included, requires a higher certificate level with additional personnel, quality-control, and proficiency-testing requirements, detailed in CMS’s own CLIA program brochure (CMS, CLIA Program and Medicare Laboratory Services brochure). Practical guidance for practicing clinicians on obtaining and maintaining the right certificate is also available through AAFP (AAFP, CLIA Certification and Waived Tests).
What “profit center” means once markup rules are accounted for
Direct answer: markup on send-out lab tests, self-referral arrangements, and fee-splitting with reference labs are regulated at both the federal and state level, and the rules on what a practice can bill a patient for a referred lab test vary significantly by state, so no single markup percentage is universally legal.
This is the part several generic profitability guides gloss over. A markup structure that is routine in one state can violate anti-markup or fee-splitting rules in another, and if any federal payer is involved, Stark Law and anti-kickback rules layer on top. Before implementing any markup strategy, confirm your specific state’s rules, ideally with a healthcare attorney or your billing compliance advisor, not with a generic percentage pulled from an industry blog.
Four ways to build margin without crossing the compliance line
- Confirm your CLIA certificate type before adding any test to your menu, not after you’ve already started ordering it.
- Route complex or send-out tests through a reference lab with transparent, disclosed pricing, rather than a hidden markup baked into the patient’s invoice.
- Bill the clinical interpretation as its own service. The value you add is reviewing and explaining the result, not marking up the specimen itself, and that interpretive work is generally the more defensible thing to charge for directly.
- Track which panels actually change a treatment plan, and drop the ones that don’t. A test menu nobody acts on clinically is a cost center dressed up as a profit center, regardless of what you charge for it.
Where this overlaps with the GLP-1 revenue conversation
This connects directly to the same shift covered in Turning Lab Testing Into a Profit Center’s sibling topic, GLP-1s Aren’t Killing Functional Medicine, They’re Creating a New Revenue Category. Patients on rapid pharmaceutical weight loss protocols increasingly need nutrient-status and metabolic-marker tracking during treatment, which is exactly the kind of interpretive, clinically-driven lab work that holds up better under compliance review than a generic markup model. The two revenue strategies reinforce each other when built on the same compliant foundation.
Where this sits in the four energy centers
Lab testing revenue sits in the sales energy center once the regulatory and delivery pieces are in place, it is a direct, billable line item tied to a specific patient decision point. Trying to build the sales case before confirming the CLIA and markup rules underneath it is building on a foundation that hasn’t been checked yet.
Who this applies to
This applies to any cash-pay or hybrid functional medicine, chiropractic, or integrative practice considering in-house point-of-care testing, an expanded send-out lab menu, or a formal lab-interpretation service line. It matters most for practices currently ordering labs without a documented CLIA certificate on file, since that is a compliance gap independent of any revenue question.
Important considerations
Confirm your state’s specific rules on lab markup, self-referral, and fee-splitting before implementing any revenue strategy described here, since these rules vary meaningfully by state and change over time. If any federal payer is involved in your billing, Stark Law and anti-kickback statute considerations apply on top of state rules. This article does not substitute for review by a healthcare attorney or billing compliance specialist familiar with your state.
Professional note and FTC compliance
This article is for informational and educational purposes only and describes general regulatory and business concepts. It is not legal advice. No specific markup percentage described here should be treated as universally legal in every state. Any claim about lab testing revenue or margin made in your own marketing must be substantiated with your practice’s own data and must not imply results that are typical for every reader’s practice.
FAQs
What decides whether I can run a test in-house?
Your CLIA certificate type. Only tests the FDA and CDC classify as CLIA-waived can be run under a basic Certificate of Waiver, and that classification, not clinical usefulness, is what governs.
Can I mark up send-out lab tests?
Markup on send-out tests, self-referral arrangements and fee-splitting with reference labs are regulated at both federal and state level, so confirm your state’s rules before building a revenue strategy on a markup.
How do I build lab margin without a compliance problem?
Confirm the certificate type first, route send-out tests through transparent reference lab pricing, bill clinical interpretation as its own service, and track which panels actually change treatment plans.
Is lab testing a marketing decision or a delivery decision?
Neither. It is realised in sales, and only once the regulatory and delivery groundwork is already in place.
The bottom line
Lab testing can be a real profit center, but only when the CLIA certificate, the markup rules, and the clinical interpretation work are all accounted for before the sales pitch is built. Getting the regulatory ceiling right first, then designing a compliant revenue structure inside it, is exactly the kind of systems work the Precision Wellness program is built to install.
Author bio
Sachin Patel, DC, is the founder of Precision Wellness Practice, a clinical and business framework program helping chiropractors, health coaches, and functional medicine doctors build automated, high-impact practices.
Build Compliant Revenue Into Your Practice
The Precision Wellness licensee program is built on clinical protocols and a delivery model that make testing part of the care pathway rather than a markup strategy.